BACKGROUND: Abnormalities in the white matter of the brain may occur in individuals with schizophrenia as well as with normal aging. Therefore, elderly schizophrenic patients may suffer further cognitive decline as they age. This study determined whether elderly schizophrenia participants, especially those with declined cognitive function (Clinical Dementia Rating score > 1), show white matter metabolite abnormalities on proton magnetic resonance spectroscopy and whether there are group differences in age-dependent changes in these brain metabolites. METHOD: Twenty-three elderly schizophrenia and twenty-two comparison participants fulfilling study criteria were enrolled. Localized, short echo-time (1)H MRS at 4 Tesla was used to assess neurometabolite concentrations in several white matter regions. RESULTS: Compared with healthy subjects, schizophrenia participants had lower N-acetyl compounds (-12.6%, p = .0008), lower myo-inositol (-16.4%, p = .026), and higher glutamate + glutamine (+28.7%, p = .0016) concentrations across brain regions. Schizophrenia participants with Clinical Dementia Rating >/= 1 showed the lowest NA in the frontal and temporal regions compared with control subjects. Interactions between age and schizophrenia status on total creatine and choline-containing compounds were observed; only schizophrenia participants showed age-related decreases of these metabolites in the right frontal region. CONCLUSIONS: Decreased NA in these white matter brain regions likely reflects reduced neuronal content associated with decreased synapses and neuronal cell volumes. The elevated glutamate + glutamine, if reflecting elevated glutamate, could result from excess neuronal glutamate release or glial dysfunction in glutamate reuptake. The decreased myo-inositol in participants with schizophrenia suggests decreased glial content or dysfunctional glia, which might result from glutamate-mediated toxicity.
BACKGROUND: Abnormalities in the white matter of the brain may occur in individuals with schizophrenia as well as with normal aging. Therefore, elderly schizophrenicpatients may suffer further cognitive decline as they age. This study determined whether elderly schizophreniaparticipants, especially those with declined cognitive function (Clinical Dementia Rating score > 1), show white matter metabolite abnormalities on proton magnetic resonance spectroscopy and whether there are group differences in age-dependent changes in these brain metabolites. METHOD: Twenty-three elderly schizophrenia and twenty-two comparison participants fulfilling study criteria were enrolled. Localized, short echo-time (1)H MRS at 4 Tesla was used to assess neurometabolite concentrations in several white matter regions. RESULTS: Compared with healthy subjects, schizophreniaparticipants had lower N-acetyl compounds (-12.6%, p = .0008), lower myo-inositol (-16.4%, p = .026), and higher glutamate + glutamine (+28.7%, p = .0016) concentrations across brain regions. Schizophreniaparticipants with Clinical Dementia Rating >/= 1 showed the lowest NA in the frontal and temporal regions compared with control subjects. Interactions between age and schizophrenia status on total creatine and choline-containing compounds were observed; only schizophreniaparticipants showed age-related decreases of these metabolites in the right frontal region. CONCLUSIONS: Decreased NA in these white matter brain regions likely reflects reduced neuronal content associated with decreased synapses and neuronal cell volumes. The elevated glutamate + glutamine, if reflecting elevated glutamate, could result from excess neuronal glutamate release or glial dysfunction in glutamate reuptake. The decreased myo-inositol in participants with schizophrenia suggests decreased glial content or dysfunctional glia, which might result from glutamate-mediated toxicity.
Authors: R A Charlton; T R Barrick; D J McIntyre; Y Shen; M O'Sullivan; F A Howe; C A Clark; R G Morris; H S Markus Journal: Neurology Date: 2006-01-24 Impact factor: 9.910
Authors: Ludger Tebartz van Elst; Gabi Valerius; Martin Büchert; Thorsten Thiel; Nicholas Rüsch; Emanuel Bubl; Jürgen Hennig; Dieter Ebert; Hans M Olbrich Journal: Biol Psychiatry Date: 2005-07-14 Impact factor: 13.382
Authors: Philip R Szeszko; Babak A Ardekani; Manzar Ashtari; Sanjiv Kumra; Delbert G Robinson; Serge Sevy; Handan Gunduz-Bruce; Anil K Malhotra; John M Kane; Robert M Bilder; Kelvin O Lim Journal: Am J Psychiatry Date: 2005-03 Impact factor: 18.112
Authors: Rajendra A Morey; Seniha Inan; Teresa V Mitchell; Diana O Perkins; Jeffrey A Lieberman; Aysenil Belger Journal: Arch Gen Psychiatry Date: 2005-03
Authors: Juan R Bustillo; Hongji Chen; Charles Gasparovic; Paul Mullins; Arvind Caprihan; Clifford Qualls; William Apfeldorf; John Lauriello; Stefan Posse Journal: Biol Psychiatry Date: 2010-10-20 Impact factor: 13.382
Authors: René C W Mandl; Martijn P van den Heuvel; Dennis W J Klomp; Vincent O Boer; Jeroen C W Siero; Peter R Luijten; Hilleke E Hulshoff Pol Journal: Hum Brain Mapp Date: 2011-06-14 Impact factor: 5.038
Authors: Allison S Brandt; Paul G Unschuld; Subechhya Pradhan; Issel Anne L Lim; Gregory Churchill; Ashley D Harris; Jun Hua; Peter B Barker; Christopher A Ross; Peter C M van Zijl; Richard A E Edden; Russell L Margolis Journal: Schizophr Res Date: 2016-02-28 Impact factor: 4.939
Authors: Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis Journal: Schizophr Res Date: 2014-01-11 Impact factor: 4.939
Authors: Anouk Marsman; Martijn P van den Heuvel; Dennis W J Klomp; René S Kahn; Peter R Luijten; Hilleke E Hulshoff Pol Journal: Schizophr Bull Date: 2011-07-11 Impact factor: 9.306
Authors: S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland Journal: Neuropsychopharmacology Date: 2016-08-26 Impact factor: 7.853
Authors: Eric Plitman; Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Sofia Chavez; Gladys Gómez-Cruz; Pablo León-Ortiz; Ariel Graff-Guerrero Journal: Schizophr Bull Date: 2015-08-28 Impact factor: 9.306